Substituted Spiro Compounds and Their Use for Producing Pain-Relief Medicaments

A substituted spiro compound corresponding to formula I

• wherein
• m is 0, 1, 2, 3 or 4,
• n is 0, 1 or 2,
• R1 represents
• an unsubstituted or mono- or polysubstituted, unsaturated or saturated cycloaliphatic group which optionally has at least one heteroatom as ring member and can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group and/or condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system,
• an unsubstituted or mono- or polysubstituted aryl or heteroaryl group which can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group and/or condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system,
• a —C(═O)—NR5R6 group,
• a —C(═S)—NR7R8 group,
• a —C(═O)—R9 group, or
• an —S(═O)2—R10 group;
• R2 represents
• a linear or branched, saturated or unsaturated, unsubstituted or mono- or polysubstituted aliphatic group optionally having at least one heteroatom as chain member;
• an unsubstituted or mono- or polysubstituted, unsaturated or saturated cycloaliphatic group which optionally has at least one heteroatom as ring member and can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group optionally having at least one heteroatom as chain member and/or condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system,
• an unsubstituted or mono- or polysubstituted phenyl group, with the proviso that either of the two meta positions and the para position of said phenyl group are not both substituted with substituents which are respectively bound to the phenyl group via an identical atom selected from the group consisting of oxygen, sulfur and nitrogen;
• an unsubstituted or mono- or polysubstituted group selected from the group consisting of naphthyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyranyl, pyridinyl, imidazolyl, indolyl, isoindolyl, benzo[b]furanyl, benzo[b]thiophenyl, thiazolyl, oxazolyl, isoxazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, indazolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, benzotriazolyl, benzisoxazolyl, [1,2,3,4]-tetrahydronaphthyl, [1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-tetrahydroisoquinolinyl, [1,2,3,4]-tetrahydroquinazolinyl;
• 2H-benzo[1.4]oxazin-3(4H)-onyl, (3,4)-dihydroquinolin-2(1H)-onyl, [3,4]-dihydro-2H-1,4-benzoxazinyl and benzothiazolyl, or
• an unsubstituted or mono- or polysubstituted aryl or heteroaryl group which is bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group optionally having at least one heteroatom as chain member and optionally can be condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system;
• R3 represents a halogen group, a nitro group, a hydroxy group, a thiol group;
• an —O—R11 group, an —S—R12 group, or a linear or branched, saturated or unsaturated, unsubstituted or mono- or polysubstituted aliphatic group;
• R4 represents hydrogen, a halogen group, a nitro group, a hydroxy group, a thiol group;
• an oxo group (═O), an —O—R11 group, an —S—R12 group, or a linear or branched, saturated or unsaturated, unsubstituted or mono- or polysubstituted aliphatic group;
• R5 and R7 each independently represent a linear or branched, saturated or unsaturated, unsubstituted or mono- or polysubstituted aliphatic group optionally having at least one heteroatom as chain member,
• an unsubstituted or mono- or polysubstituted, unsaturated or saturated cycloaliphatic group which optionally has at least one heteroatom as ring member and can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group optionally having at least one heteroatom as chain member and/or condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system and/or bridged with at least one linear or branched, unsubstituted or mono- or polysubstituted alkylene group,
• an unsubstituted or mono- or polysubstituted aryl or heteroaryl group which can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group optionally having at least one heteroatom as chain member and/or condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system,
• R6 and R8 each independently represent
• hydrogen,
• a linear or branched, saturated or unsaturated, unsubstituted or mono- or polysubstituted aliphatic group optionally having at least one heteroatom as chain member,
• an unsubstituted or mono- or polysubstituted, unsaturated or saturated cycloaliphatic group which optionally has at least one heteroatom as ring member and can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group optionally having at least one heteroatom as chain member and/or condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system and/or bridged with at least one linear or branched, unsubstituted or mono- or polysubstituted alkylene group,
• an unsubstituted or mono- or polysubstituted aryl or heteroaryl group which can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group optionally having at least one heteroatom as chain member and/or condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system,
• R9 and R10 each independently represent
• a linear or branched, saturated or unsaturated, unsubstituted or mono- or polysubstituted aliphatic group;
• an unsubstituted or mono- or polysubstituted, unsaturated or saturated cycloaliphatic group which optionally has at least one heteroatom as ring member and can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group and/or condensed with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system;
• or
• an unsubstituted or mono- or polysubstituted aryl or heteroaryl group which can be bound via a linear or branched, unsubstituted or mono- or polysubstituted alkylene, alkenylene or alkinylene group and/or condensed
• with an unsubstituted or mono- or polysubstituted mono- or polycyclic ring system;
• and
• R11 and R12 each independently represent
• a linear or branched, saturated or unsaturated, unsubstituted aliphatic group;
• an unsubstituted, unsaturated or saturated cycloaliphatic group which optionally has at least one heteroatom as ring member and can be bound via a linear or branched, unsubstituted alkylene, alkenylene or alkinylene group and/or condensed with an unsubstituted mono- or polycyclic ring system, or
• an unsubstituted aryl or heteroaryl group which can be bound via a linear or branched, unsubstituted alkylene, alkenylene or alkinylene group and/or condensed with an unsubstituted mono- or polycyclic ring system;
• wherein the substituents of the above-mentioned aliphatic groups can be independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —SH and —NH2;
• or a salt of solvate thereof.